The Methylated Septin 9 test is a sensitive blood-based colorectal cancer screening test using the SEPT9 biomarker. This test specifically detects a majority of colorectal cancer of all stages and colorectal locations. The test is an alternative for those who are unwilling to undergo a colonoscopy.
About half of Americans 50 to 75 years old do not follow recommended colorectal cancer screening guidelines, leaving 40 million individuals unscreened. A simple blood test would increase screening compliance, promoting early detection and better patient outcomes.